Vanda Pharmaceuticals Inc.
General ticker "VNDA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $271.5M (TTM average)
Vanda Pharmaceuticals Inc. follows the US Stock Market performance with the rate: 35.6%.
Estimated limits based on current volatility of 3.3%: low 7.08$, high 7.56$
Factors to consider:
- Total employees count: 368 (+81.3%) as of 2024
- Countries other than US accounted for 5.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Dependence on key products, Reimbursement risks, Regulatory and compliance, Manufacturing risks, Market competition
- Current price 26.1% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.05$, 6.23$]
- 2025-12-31 to 2026-12-31 estimated range: [2.87$, 5.92$]
Financial Metrics affecting the VNDA estimates:
- Positive: with PPE of -14.8 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -5.72 <= 0.04
- Positive: Inventory ratio change, % of 0.16 <= 0.82
- Positive: -3.57 < Return on assets ratio (scaled to [-100,100]) of -2.80
- Positive: -14.19 < Investing cash flow per share per price, % of -6.32
- Positive: Shareholder equity ratio, % of 82.07 > 64.17
Short-term VNDA quotes
Long-term VNDA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $254.38MM | $192.64MM | $198.77MM |
| Operating Expenses | $248.05MM | $206.59MM | $239.43MM |
| Operating Income | $6.33MM | $-13.95MM | $-40.66MM |
| Non-Operating Income | $4.97MM | $20.29MM | $17.74MM |
| R&D Expense | $85.77MM | $76.82MM | $74.43MM |
| Income(Loss) | $11.30MM | $6.34MM | $-22.92MM |
| Taxes | $5.03MM | $3.83MM | $-4.02MM |
| Profit(Loss)* | $6.28MM | $2.51MM | $-18.90MM |
| Stockholders Equity | $527.20MM | $544.91MM | $538.55MM |
| Inventory | $1.19MM | $1.36MM | $1.73MM |
| Assets | $634.25MM | $648.44MM | $656.20MM |
| Operating Cash Flow | $31.98MM | $12.80MM | $-15.76MM |
| Capital expenditure | $0.68MM | $0.38MM | $0.49MM |
| Investing Cash Flow | $49.92MM | $-12.06MM | $-17.43MM |
| Financing Cash Flow | $0.73MM | $0.00MM | $-0.15MM |
| Earnings Per Share** | $0.11 | $0.04 | $-0.33 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.